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MRI preclinical detection and asymptomatic course of
a progressive multifocal leucoencephalopathy (PML)
under natalizumab therapy
Rémy Phan-Ba,1 Emilie Lommers,1 Luaba Tshibanda,2 Philippe Calay,1
Bernard Dubois,3 Gustave Moonen,1 David Clifford,4 Shibeshih Belachew1
ABSTRACT
Early detection of progressive multifocal
leucoencephalopathy (PML) in the setting of natalizumab
therapy currently is performed by rapid evaluation of new
symptoms occurring in treated patients. The role of MR
scanning has not been investigated but holds promise
since MR detection is highly sensitive for PML lesions.
The authors report a case of presymptomatic PML of the
posterior fossa detected by MR scans. Immediate
suspension of natalizumab and plasma exchanges
resulted in a rapid decline of natalizumab serum
concentration. Intravenous steroids started together with
plasma exchanges followed by an oral tapering course
were used to minimise the immune reconstitution
inflammatory syndrome. No symptoms (beyond mild
headache) developed, and the repeat PCR for JC Virus
(JCV) DNA detection performed 10 weeks later was
negative. This case suggests that: (1) periodic brain MR
scans may detect signs of presymptomatic PML in MS
patients treated with natalizumab, (2) corticosteroid
management of inflammatory reaction may contribute to
optimal control of the immune reconstitution
inflammatory syndrome routinely seen with natalizumab-
associated PML and (3) early radiological detection of
PML can have an excellent outcome even in a clinically
critical region and despite prior immunosuppressant
exposure. The potential benefit of regular MR scanning
just using the T2/FLAIR modalities could be further
investigated in order to detect early natalizumab-
associated PML, leading to benign outcomes.
CASE REPORT
A 29-year-old man diagnosed 17 years earlier with
relapsing multiple sclerosis (RMS) remained free of
disease activity during 3 years of natalizumab
therapy in that he experienced no clinical relapses,
disability progression and no new T2 or gadolinium
(Gd) enhancing T1 lesions on five successive follow-
up brain MRI. He had no other significant comor-
bidities. The patient’s previous RMS therapy
included 4 years of interferon b-1b and six courses
of mitoxantrone (12 mg/m2 dosed every 2 months,
3 years before initiating natalizumab), which failed
to control disease activity. After 153 weeks of
natalizumab therapy (38 doses of 300 mg intrave-
nous every 4 weeks) our patient’s sixth routine
6-month follow-up MRI scan depicted six small
(1.0 to 3.0 mm) new lesions in the left middle
cerebellar peduncle with faint T1 Gd enhancement
(figure 1). Consequently, at the 39th scheduled
natalizumab infusion (week 153), dosing was
suspended, and a cranial MRI 3 weeks later
demonstrated a major worsening of the punctuate-
shape lesion pattern with 49 small (1.0e5.2 mm)
Gd-enhancing lesions in the left middle cerebellar
peduncle and left cerebellar hemisphere (week 156,
figure 1). Most lesions were also hyperintense in
diffusion-weighted imaging, and no oedema or
meningeal enhancement was observed. The supra-
tentorial MS lesions were strictly stable in number
and volume with no Gd enhancement (figure 2,
supplementary material). The only new complaint
expressed by the patient was a mild occipital
headache lasting 3e4 days, but his neurological
examination remained unchanged and the
Expanded Disability Status Scale score was stable at
4.0, as were several functional assessments such as
the Timed 25-Foot Walk test,1 2 the Six-Spot-Step
Test,3 the Timed 100 m Walk test,4 the Nine-Hole
Peg Test1 2 and the 3 s Paced Auditory Serial Addi-
tion Test1 2 (figure 3, supplementary material). The
cerebrospinal fluid analysis (CSF) showed a plei-
ocytosis with 81 white blood cells (91% lympho-
cytes, 9% monocytes) and eight red blood cells/
mm3. The glucose concentration was within the
normal range (0.64 g/l), and the protein concen-
tration was mildly elevated (507 mg/l). The IgG
was elevated at 50 mg/l, and numerous CSF-specific
oligoclonal bands were observed. JC polyoma virus
(JCV) DNA was detected in CSF using ultrasensi-
tive quantitative real-time PCR (Focus Diagnostics,
Cypress, California) (712 copies/ml), and serum
anti-JCV antibodies were detected using a two-step
ELISA as previously described.5 Other CSF and
blood analysis were unremarkable (table 1, supple-
mentary material). Based on these observations, we
confirmed a diagnosis of asymptomatic progressive
multifocal leucoencephalopathy (PML) in the
posterior fossa, with an atypical punctuate-shape
pattern (week 156). In order to hasten the clearance
of natalizumab, we carried out only three plasma
exchanges (PLEX, 1.5 volumes) since the last nata-
lizumab infusion had been dosed, 7 weeks before
PML diagnosis, with the possible presence of early
MRI signs of immune reconstitution inflammatory
syndrome (IRIS). Intravenous methylprednisolone
(IVMP, 1 g) was initiated together with the PLEX
for 5 days, followed by an oral tapering course of
12 weeks, in order to silence the radiological IRIS.
After PLEX had been performed, we were informed
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Liège, Belgium
2Department of Neuroradiology,
CHU of Liege, Liège, Belgium
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that natalizumab serum concentration was already below the
limits of quantitation of the assay (ie, <0.5 mg/ml) before PLEX.
The patient remained strictly symptom-free throughout
a follow-up of 19 weeks after the last natalizumab infusion,
15 weeks after the first MRI signs of PML and 12 weeks after
PLEX (figure 2, supplementary material). Ten weeks after PML
diagnosis and onset of PLEX-IVMP treatment, a follow-up assay
using ultrasensitive PCR indicated that CSF was negative for JC
virus DNA. The CSF pleiocytosis had vanished with four white
blood cells/mm3, and protein concentration decreased at
426 mg/l. At the time the CSF was normalised (week 166), the
follow-up brain MRI scans showed a regression of the PML
lesion volume on T2/FLAIR sequences with a partial resolution
of T1-Gd enhancement, particularly at the periphery of the
lesion (figure 1). Brain MRI scans performed at weeks 157, 159
and 162 displayed intermediate lesion patterns consistent with
the demonstration of a gradual radiological improvement
between week 156 and 166 (data not shown).
DISCUSSION
Natalizumab is a highly effective therapy for RMS6 but
increased exposure has been associated with an increased risk of
PML, which is a potentially life-threatening central-nervous-
system infection of oligodendrocytes by the JC polyoma virus.7
Despite an increased risk of PML in patients with known risk
factors such as prior use of immunosuppressive agents and
natalizumab treatment duration of more than 2 years, no clear
guidelines have yet been drawn, and clinical vigilance remains
the primary tool for early PML diagnosis. There is an ongoing
debate about how to appropriately stratify PML risk in natali-
zumab-treated patients.5 8 It was recently reported that anti-
JCV antibodies were detected in 100% of PML patients from
whom pre-PML serum samples were available up to 187 months
prior to clinical diagnosis,5 and as such, anti-JCV antibody
serostatus is being investigated as potential additional factor to
stratify PML risk.
Since the initial clinical manifestations of PML can be subtle
(including isolated mild cognitive changes), it is not surprising
that the time between the onset of symptoms and PML diag-
nosis can vary considerably, from a few days to several months.7
The management of natalizumab-associated PML is also
a matter of debate. A prompt wash-out of serum natalizumab,
either by PLEX or by immunoadsorption, in order to hasten the
restoration of CNS immune surveillance, combined with steroid
therapy to prevent IRIS development, is common practice for
PML treatment. Recently, it has been reported in a group of 35
Figure 1 T2-weighting with fluid
attenuation inversion recovery (FLAIR)
and T1+Gd MR images of two
scanning plans separated by 8 mm in
the posterior fossa at different stages of
a patient’s history with reference to the
onset of natalizumab therapy. Week
129 examination was the fifth routine
6-monthly brain MR scan. Week 153
shows the first MR signs of the
punctate-shape PML lesion in the left
cerebellar peduncle. FLAIR-
hyperintense dots (arrow) were all Gd-
enhanced on T1-weighted images. At
the time PML diagnosis was
ascertained at week 156, the lesion
massively extended to the left
cerebellar hemisphere. When no more
JC virus DNA was detectable on the
CSF at week 166, we observed
a significant regression of the multifocal
lesion volume on FLAIR images
together with an increased
coalescence. The aspect of Gd
enhancement was also modified and
then restricted to the central core of the
lesion with a decrease in dotted
peripheral enhancement in the
cerebellar hemisphere.
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natalizumab-treated PML cases that enhanced clinical vigilance,
including early recognition of symptoms, diagnosis and aggres-
sive management of PML and IRIS are associated with an
improved survival rate and clinical outcomes.9 However, the
precise approach should be optimised for each patient with
attention to MRI characteristics of PML (including early signs of
IRIS) and of the natalizumab serum concentration at the time of
PML diagnosis.
In our department, we perform 6-monthly brain MRI scans
for all RMS patients treated with natalizumab. In the case of the
patient reported here, the MRI features were somewhat
unusual. In particular, the punctuate pattern is atypical and
might be due to tiny multifocal foci of JC virus proliferation that
later coalesce to give rise to the classical appearance of a wide-
spread white-matter disorder and symptoms. Whereas the Gd
enhancement is rare in HIV-related PML, it is commonly
observed in the context of natalizumab therapy. Gd enhance-
ment of the PML lesions may reflect a breakdown of the
bloodebrain barrier due to early IRIS10 associated with the rapid
decline of natalizumab serum concentration, which was already
undetectable here when the first lesions were observed. Finally,
the rapid deterioration of the PML lesion load observed within
3 weeks after the first MRI signs is a strong argument to plead
for a rapid CSF screening for JC virus DNA in the context of
any new unusual brain lesion in MS patients treated with
natalizumab.8
This case emphasises that JC virus CNS infection can be
detected at a preclinical stage, even in the posterior fossa where
small lesions often cause serious disability. The uncoupling
between a large PML lesion in a highly functional location, and
the absence of clinical expression, is of great interest. In this case,
an aggressive corticosteroid regimen initiated during PLEX was
associated with a stable clinical course of PML, a favourable
evolution of MRI manifestations and clearance of JC virus from
CSF. Although the benefits of steroids in natalizumab-associated
PML-IRIS have never been and will never be addressed in
a randomised clinical trial, at least one study has suggested
a clinical benefit in PML-IRIS with HIV infection.11 Since the
theoretical risk of increasing the JC virus load during steroid
therapy is considered low with regard to the likelihood of
developing detrimental IRIS, many experts have advocated
high-dose steroid treatment use in the context of natalizumab-
associated PML.7 12 13
One prior reported case suggests that asymptomatic MRI
changes can be captured several months prior to initial mani-
festation of PML symptoms.14 The story of the present case
suggests that the screening for preclinical signs of PML might be
achieved through periodic T2/FLAIR brain MRI scans in patients
with known PML risk factors such as prior immunosuppressant
exposure, natalizumab treatment duration over 2 years and JC
virus seropositivity. However, the required frequency, coste
benefit trade-off and efficacy of such a monitoring remain to be
investigated before we firmly consider that it may increase the
proportion of early detection of PML in such patients, and
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